Orris

35-year-old male, municipality worker visited a camp with 5 productive cough since a month with intermittent fever. He reported evening rise of temperature on most days. His 'spot sputum sample' was collected, which on Ziehl- Neelsen stain showed reddish bacill: 2+. A portion of the sample was sent fornucleic acid amplification testing which showed that the micro- organism is present and it is sensitive to Rifampicin. Essays a) What is your djagnosis [KU 24] b) Write the management plan for this individual assuming his weight to be 55 kg. C) What are the advices to be given to reduce further transmission of the disease. d) He lives with 30-year-old wife and two sons aged 9 years and 4 years. How would you ensure that the disease is not spread to these family members. e) Write about immuno prophylaxis available against the disease

Reading File
Finding Sources
Finding Sources
Searching PubMed

tuberculosis preventive treatment AND household contacts

Searching the Web

India NTEP drug susceptible tuberculosis treatment 2025 adult weight band 50 64 kg household contact preventive treatment

Finding Sources
Finding Sources
Reading Web Page

https://tbcindia.mohfw.gov.in/wp-content/uploads/2023/05/Gui…

Searching PubMed

BCG vaccination tuberculosis systematic review

Reading File

a) Diagnosis

Bacteriologically confirmed, rifampicin-sensitive pulmonary tuberculosis (drug-susceptible pulmonary TB), smear-positive (AFB 2+), new case.
Basis:
  • Chronic productive cough, intermittent fever with evening rise
  • Ziehl-Neelsen sputum smear: acid-fast bacilli, 2+
  • NAAT: Mycobacterium tuberculosis detected and rifampicin resistance not detected

b) Management plan for this 55 kg man

1. Notify and register

  • Notify through Nikshay/NTEP and start treatment promptly.
  • Allocate a treatment supporter or digital adherence support.
  • Assess adherence barriers, nutrition, substance use, diabetes, HIV risk, and household contacts.

2. Start daily anti-tuberculosis treatment

This is drug-susceptible pulmonary TB, so prescribe:
PhaseDurationRegimenDose for 55 kg
Intensive phase2 months, 56 daily dosesHRZE4 tablets daily of 4-FDC
Continuation phase4 months, 112 daily dosesHRE4 tablets daily of 3-FDC
For the NTEP adult 50-64 kg weight band, each day he receives:
Intensive phase: 4 tablets of HRZE FDC
  • Isoniazid (H): 300 mg
  • Rifampicin (R): 600 mg
  • Pyrazinamide (Z): 1,600 mg
  • Ethambutol (E): 1,100 mg
Continuation phase: 4 tablets of HRE FDC
  • Isoniazid: 300 mg
  • Rifampicin: 600 mg
  • Ethambutol: 1,100 mg
Thus the regimen is 2 HRZE / 4 HRE, daily, under adherence support. A six-month RIPE-based regimen is the standard approach for drug-susceptible pulmonary TB, as described in the standard treatment reference.

3. Baseline evaluation

  • Detailed history and examination, including weight and nutritional assessment.
  • Chest radiograph.
  • HIV test after consent.
  • Screen for diabetes mellitus, ideally blood glucose/HbA1c.
  • Liver function tests if liver disease, alcohol use, malnutrition, HIV, pregnancy, or symptoms suggest liver disease.
  • Test visual acuity and red-green colour vision before ethambutol if feasible.
  • Complete drug-susceptibility testing as per local NTEP algorithm, especially if prior TB treatment, known drug-resistant TB contact, or poor response.

4. Follow-up and monitoring

  • Monthly clinical review: symptoms, weight, adherence, adverse effects.
  • Readjust FDC dose if weight crosses into another band.
  • Sputum smear examination at the end of intensive phase and at treatment completion, or as per local programme protocol.
  • Assess for treatment failure if symptoms persist or sputum remains positive late in treatment. Obtain culture and drug-susceptibility testing if there is delayed response.

5. Adverse-effect counselling

Ask him to report:
  • Jaundice, anorexia, nausea/vomiting, severe abdominal pain: possible hepatotoxicity from H/R/Z.
  • Visual blurring or defective red-green colour discrimination: ethambutol toxicity.
  • Numbness or tingling of hands/feet: isoniazid neuropathy.
  • Rash, fever, bleeding tendency.
  • Rifampicin can cause harmless orange-red discoloration of urine, tears, sweat, and saliva. It also has important drug interactions.
Give pyridoxine, especially if malnourished, diabetic, alcohol-dependent, HIV-positive, pregnant, or with neuropathy risk. A commonly used preventive dose is 10-25 mg daily.

c) Advice to reduce further transmission

  1. Take every dose without interruption. Effective treatment rapidly reduces infectiousness, commonly within about 2 weeks when treatment is appropriate and adhered to.
  2. Wear a well-fitting mask, especially in crowded indoor places and while coughing during the initial phase of treatment.
  3. Follow cough etiquette:
    • Cover nose and mouth while coughing/sneezing.
    • Use a tissue or elbow, not bare hands.
    • Dispose of sputum/tissues safely in a covered container or toilet.
    • Do not spit in public places.
  4. Keep rooms well ventilated: open windows and doors; maximize sunlight and outdoor air.
  5. Avoid prolonged close indoor exposure, crowded workspaces, and poorly ventilated gatherings until improving on treatment.
  6. Sleep separately and avoid close indoor contact with young children during the early infectious period, if practical.
  7. Avoid smoking, tobacco, alcohol excess, and undernutrition. Ensure a protein- and calorie-adequate diet.
  8. Ensure household and workplace contact evaluation. His municipality-work colleagues with prolonged close exposure should be symptom-screened according to local public-health procedure.
  9. TB is spread through inhalation of airborne droplet nuclei, not by sharing food, utensils, clothing, or casual touch. Do not stigmatize or isolate him unnecessarily.

d) Protecting the wife and two children

Step 1: Immediate household contact investigation

List all household contacts and ask about:
  • Cough, fever, night sweats, weight loss, poor appetite, fatigue
  • In children: failure to gain weight, persistent fever/cough, reduced playfulness
All three contacts should have a clinical assessment and chest radiograph where indicated. Anyone symptomatic or with an abnormal chest radiograph requires sputum testing or age-appropriate bacteriological testing.

Step 2: Specific plan for each family member

Household memberAction
Wife, 30 yearsSymptom screen, chest radiograph, test for TB infection where available, and investigate promptly if symptomatic. After active TB is excluded, assess eligibility for TB preventive treatment.
Son, 9 yearsUrgent symptom screen and clinical evaluation. Chest radiograph and TB infection test where available. If active TB is ruled out, offer TB preventive treatment according to NTEP protocol.
Son, 4 yearsHighest priority because he is under 5 years. Exclude active TB clinically and with chest radiograph. If active TB is excluded, begin TB preventive treatment without delay.
Under India’s NTEP policy, household contacts of pulmonary TB patients should be screened, and preventive treatment should be offered after active TB has been ruled out. The programme recommends 3 months of once-weekly isoniazid plus rifapentine (3HP) for eligible persons aged over 2 years, with 6 months of daily isoniazid (6H) as an alternative in relevant settings. See the NTEP preventive-treatment guidance.

Step 3: Home measures

  • Maintain cross-ventilation.
  • The patient should wear a mask around children in the initial treatment period.
  • The 4-year-old should avoid prolonged close time in the same poorly ventilated room as the patient until he has improved on effective treatment.
  • Ensure that the children’s routine immunisations, nutrition, growth monitoring, and school attendance support are maintained.
  • Do not give the children treatment for active TB unless disease is found. Preventive treatment is used only after active disease has been excluded.
Recent systematic reviews support systematic screening of household contacts; see PMIDs 41964650 and 41386250. This does not change the core NTEP approach above.

e) Immunoprophylaxis: BCG vaccine

Vaccine

  • BCG means Bacille Calmette-Guérin vaccine.
  • It is a live attenuated strain of Mycobacterium bovis.

Schedule in India

  • Given routinely under the Universal Immunisation Programme.
  • Administered at birth or as early as possible, by the intradermal route in the left upper arm.
  • Dose:
    • 0.05 mL for infants below 1 year
    • 0.1 mL for persons aged 1 year or more

Protection offered

BCG is mainly effective in protecting young children against severe forms of TB:
  • TB meningitis
  • Miliary/disseminated TB
  • Severe primary childhood TB
It provides variable and limited protection against adult pulmonary TB and does not replace contact screening, early diagnosis, treatment, or TB preventive treatment. Textbook sources describe BCG as particularly protective against severe disseminated childhood TB, rather than reliably preventing adult pulmonary disease.

Adverse effects

  • Local papule followed by ulcer and scar formation is expected.
  • Local lymphadenitis may occur.
  • Rarely: suppurative lymphadenitis, osteitis, or disseminated BCG infection.

Contraindications

  • Severe immunodeficiency, including severe/symptomatic HIV infection.
  • Children receiving significant immunosuppressive treatment.
  • Do not give BCG to a person with active TB as treatment or post-exposure prophylaxis.
For this family, check whether both sons received BCG at birth. BCG revaccination is not routinely indicated, and the 4-year-old should still receive contact evaluation and TB preventive treatment if active disease is excluded.
This is a shared conversation. Sign in to Orris to start your own chat.